GLP-1受体激动剂与糖尿病视网膜病变及血管生成:AngioSafe 2型糖尿病研究
AngioSafe T2D研究通过临床队列和随机试验及临床前模型,探讨GLP-1RA与糖尿病视网膜病变(DR)及血管生成的关系。利拉鲁肽对循环造血祖细胞和血管生成miRNA无影响,Exendin-4在体外和体内均未影响血管生成。结论认为GLP-1RA不促进血管生成,与严重DR无关。
要点
- 利拉鲁肽未改变循环造血祖细胞及血管生成miRNA水平。
- Exendin-4在体外和体内均未显示促血管生成或抑制视网膜新生血管的作用。
核心结论
- GLP-1RA对血管生成无影响,且与严重糖尿病视网膜病变无关联。
研究设计与样本
- 研究1为队列研究,纳入3154例T2D患者,分析GLP-1RA暴露与视网膜成像诊断的DR严重程度的关系。
- 研究2为随机4周试验,评估利拉鲁肽对循环造血祖细胞和血管生成miRNA的影响。
- 临床前研究评估Exendin-4对人内皮细胞增殖、存活、三维血管形态发生及小鼠视网膜缺血诱导新生血管化的影响。
主要发现
- 利拉鲁肽对循环造血祖细胞和血管生成miRNA无影响。
- 体外实验显示Exendin-4对人内皮细胞增殖、存活及毛细血管总长度和数量无影响。
- 体内实验显示Exendin-4对小鼠视网膜新生血管化无负面效应。
临床怎么用
- 对于T2D患者,使用GLP-1RA无需过度担忧加重或诱发严重糖尿病视网膜病变的风险。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: Recent trials provide conflicting results on the association between glucagon-like peptide 1 receptor agonists (GLP-1RA) and diabetic retinopathy (DR). The aim of the AngioSafe type 2 diabetes (T2D) study was to determine the role of GLP-1RA in angiogenesis using clinical and preclinical models. METHODS: We performed two studies in humans. In study 1, we investigated the effect of GLP-1RA exposure from T2D diagnosis on the severity of DR, as diagnosed with retinal imaging (fundus photography). In study 2, a randomized 4-week trial, we assessed the effect of liraglutide on circulating hematopoietic progenitor cells (HPCs), and angio-miRNAs.We then studied the experimental effect of Exendin-4, on key steps of angiogenesis: in vitro on human endothelial cell proliferation, survival and three-dimensional vascular morphogenesis; and in vivo on ischemia-induced neovascularization of the retina in mice. RESULTS: In the cohort of 3154 T2D patients, 10% displayed severe DR. In multivariate analysis, sex, disease duration, glycated hemoglobin (HbA1c), micro- and macroangiopathy, insulin therapy and hypertension remained strongly associated with severe DR, while no association was found with GLP-1RA exposure (o 1.139 [0.800-1.622], P = .47). We further showed no effect of liraglutide on HPCs, and angio-miRNAs. In vitro, we demonstrated that exendin-4 had no effect on proliferation and survival of human endothelial cells, no effect on total length and number of capillaries. Finally, in vivo, we showed that exendin-4 did not exert any negative effect on retinal neovascularization. CONCLUSIONS: The AngioSafe T2D studies provide experimental and clinical data confirming no effect of GLP-1RA on angiogenesis and no association between GLP-1 exposure and severe DR.
引用
- Gaborit B, Julla JB, Besbes S, et al. Glucagon-like Peptide 1 Receptor Agonists, Diabetic Retinopathy and Angiogenesis: The AngioSafe Type 2 Diabetes Study. J Clin Endocrinol Metab. 2020. PMID: 31589290. doi:10.1210/clinem/dgz069
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。